Altshuler Shaham’s CVS Health CVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-325
Closed -$24.5K 418
2025
Q3
$24.5K Buy
325
+47
+17% +$3.22K ﹤0.01% 180
2025
Q2
$19.2K Sell
278
-53
-16% -$3.48K ﹤0.01% 174
2025
Q1
$22.4K Sell
331
-116
-26% -$6.94K ﹤0.01% 158
2024
Q4
$20.1K Buy
447
+49
+12% +$2.75K ﹤0.01% 242
2024
Q3
$25K Sell
398
-78
-16% -$4.55K ﹤0.01% 132
2024
Q2
$28.1K Buy
476
+94
+25% +$5.88K ﹤0.01% 130
2024
Q1
$30.5K Sell
382
-188
-33% -$14.4K ﹤0.01% 133
2023
Q4
$45K Sell
570
-197
-26% -$14K ﹤0.01% 124
2023
Q3
$53.6K Sell
767
-490
-39% -$34.7K ﹤0.01% 146
2023
Q2
$86.9K Buy
+1,257
New +$89.4K ﹤0.01% 151
2022
Q4
Sell
-43
Closed -$4K 489
2022
Q3
$4K Sell
43
-316
-88% -$31.3K ﹤0.01% 421
2022
Q2
$33K Sell
359
-3,533
-91% -$345K ﹤0.01% 304
2022
Q1
$394K Buy
3,892
+1,631
+72% +$171K ﹤0.01% 187
2021
Q4
$233K Buy
2,261
+188
+9% +$17.4K ﹤0.01% 238
2021
Q3
$177K Buy
2,073
+828
+67% +$69.4K ﹤0.01% 272
2021
Q2
$104K Buy
+1,245
New +$102K ﹤0.01% 321
2020
Q2
Sell
-216
Closed -$13K 399
2020
Q1
$13K Sell
216
-80
-27% -$5.34K ﹤0.01% 265
2019
Q4
$22K Buy
+296
New +$20.8K ﹤0.01% 248

Other funds holding CVS

Altshuler Shaham's CVS Position: Q4 2025 in Review

Altshuler Shaham sold out of CVS Health (CVS) in Q4 2025, closing a stake of 325 shares — an estimated $24.5K sold.

Altshuler Shaham first reported a position in CVS in Q4 2019 and held it in 18 quarters. The position peaked at $394K in Q1 2022. 1,948 funds tracked by Wall St. Rank hold CVS as of Q4 2025.

  • Altshuler Shaham reported no remaining CVS Health position as of Q4 2025 after selling out during the quarter.
  • Altshuler Shaham sold 325 CVS Health shares in Q4 2025, an estimated $24.5K.
  • Altshuler Shaham first reported a position in CVS Health in Q4 2019 and held it in 18 quarters.
  • Altshuler Shaham's CVS Health position peaked at $394K in Q1 2022.
  • 1,948 funds tracked by Wall St. Rank held CVS Health as of Q4 2025.

Based on Altshuler Shaham's 13F filing for Q4 2025, filed 17 Feb 2026.